臨床泌尿器科74巻10号

2020年09月発行

綜説

プアリスク精巣腫瘍診療の最近の進歩

著者： 河合弘二¹ 宮崎淳¹

所属機関： ¹国際医療福祉大学医学部腎泌尿器外科学教室

ページ範囲：P.719 - P.725

要旨

　1987年に開発されたBEP療法は現在も精巣腫瘍の標準的一次化学療法であり，これを凌ぐレジメンは開発されていない．一方で，精巣腫瘍の治療成績は予後不良群を中心に確実に改善した．その要因として，治療強度を維持したBEP療法と的確な手術療法の普及，高リスク群の中核施設での管理などが挙げられる．また，精巣腫瘍治療中の重篤な合併症に関する知見の集積とリスク評価の進歩も大きく寄与している．国際的な予後評価としてのIGCC分類は1997年に提唱され，その後の臨床研究の進展に大きく寄与した．一方で，治療成績の向上をふまえて近い将来，新しいIGCC分類が提唱される予定である．本稿では，これらの最近の動向について概説した．

参考文献

1） Hanna N, et al : Testicular Cancer : A Reflection on 50 Years of Discovery. J Clin Oncol 32 : 3085-3092, 2014

2） Kawai K, et al : Current Status of Chemotherapy in Risk-Adapted Management for Metastatic Testicular Germ Cell Cancer. Cancer Sci 101 : 22-28, 2010

3） Krege S, et al : European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer : A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group （EGCCCG） : Part II. Eur Urol 53 : 497-513, 2008

4） Motzer RJ, et al : Phase III Randomized Trial of Conventional-Dose Chemotherapy with or without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue as First-Line Treatment for Patients with Poor-Prognosis Metastatic Germ Cell Tumors. J Clin Oncol 25 : 247-256, 2007

5） Fizazi K, et al : Personalised Chemotherapy Based on Tumour Marker Decline in Poor Prognosis Germ-Cell Tumours （GETUG 13） : A Phase 3, Multicentre, Randomised Trial. Lancet Oncol 15 : 1442-1450, 2014

6） Fizazi K, et al : Mature Results of the GETUG 13 Phase III Trial in Poor-Prognosis Germ-Cell Tumors （GCT）. J Clin Oncol 34 : 4504-4505, 2017

7） Feldman DR, et al : Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol 34 : 2478-2483, 2016

8） Feldman DR, et al : Multicenter Randomized Phase 2 Trial of Paclitaxel, Ifosfamide, and Cisplatin Versus Bleomycin, Etoposide, and Cisplatin for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors.　https://www.urotoday.com/conference-highlights/asco-2018/

9） Lawrence NJ, et al : Long-Term Outcomes of Accelerated BEP （Bleomycin, Etoposide, Cisplatin） for Advanced Germ Cell Tumours : Updated Analysis of an Australian Multicentre Phase II Trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group （ANZUP）. Ann Oncol 27 : 2302-2303, 2016

10） Lawrence NJ, et al : Protocol for the P3BEP Trial （ANZUP 1302） : An International Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Paediatric Male and Female Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours. BMC Cancer 18 : 854, 2018

11） International Germ Cell Cancer Collaborative Group : International Germ Cell Consensus Classification : A Prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers. J Clin Oncol 15 : 594-603, 1997

12） Kojima T, et al : Identification of a Subgroup with Worse Prognosis Among Patients with Poor-Risk Testicular Germ Cell Tumor. Int J Urol Oct 22 : 923-927, 2015

13） Gillessen S, et al : Redefining the IGCCCG Classification in Advanced Non-Seminoma. Ann Oncol 30 （suppl 5） : v356-v402, 2019

14） Laguna MP, et al : European Association of Urology （EAU） : Testicular Cancer Guidelines, 2019　https://uroweb.org/guideline/testicular-cancer/ （2020年9月11日閲覧）

15） Kawai K, et al : Completion and Toxicity of Induction Chemotherapy for Metastatic Testicular Cancer : An Updated Evaluation of Japanese Patients. Jpn J Clin Oncol 36 : 425-431, 2006

16） Inai H, et al : Oncological Outcomes of Metastatic Testicular Cancers Under Centralized Management Through Regional Medical Network. Jpn J Clin Oncol 43 : 1249-1254, 2013

17） Einhorn LH, et al : Bleomycin, Etoposide, and Cisplatin for Three Cycles Compared with Etoposide and Cisplatin for Four Cycles in Good-Risk Germ Cell Tumors : Is There a Preferred Regimen? J Clin Oncol 24 : 2597-2598, 2006

18） Kojo K, et al : Recent Malignant Testicular Tumor Trend in Japan, a Country with an Aging Population : A Large-Scale Study of 2012-2015 Hospital-Based Cancer Registry Data. Jpn J Clin Oncol, 2020 : hyaa110. doi : 10.1093/jjco/hyaa110.

19） Ruf CG, et al : Changes in Epidemiologic Features of Testicular Germ Cell Cancer : Age at Diagnosis and Relative Frequency of Seminoma Are Constantly and Significantly Increasing. Urol Oncol 32 : 33.e1-6, 2014

20） Feldman DR, et al : Clinical Features, Presentation, and Tolerance of Platinum-Based Chemotherapy in Germ Cell Tumor Patients 50 Years of Age and Older. Cancer 119 : 2574-2581, 2013

21） Rejlekova K, et al : Severe Complications in Testicular Germ Cell Tumors : The Choriocarcinoma Syndrome. Front Endocrinol （Lausanne） 10 : 218, 2019

22） Beyer J, et al : Maintaining Success, Reducing Treatment Burden, Focusing on Survivorship : Highlights from the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer. Ann Oncol 24 : 878-888, 2013

23） 黒部匡広, 他 : 転移期精巣腫瘍における腫瘍崩壊症候群 （Tumor lysis syndrome ; TLS） のリスク評価とTLS発症頻度. 泌紀62 : 237-242, 2016

24） 日本臨床腫瘍学会 （編） : 腫瘍崩壊症候群ガイダンス. 金原出版, 東京, 2013

25） Oosting SF, et al : Prevalence of Paraneoplastic Hyperthyroidism in Patients with Metastatic Non-Seminomatous Germ-Cell Tumors. Ann Oncol 21 : 104-108, 2010

26） Tilbrook LK, et al : Testicular Germ Cell Tumour Presenting as Thyrotoxicosis. Ann Clin Biochem 41 （Pt 3） : 248-249, 2004

27） Khorana AA, et al : Development and Validation of a Predictive Model for Chemotherapy-Associated Thrombosis. Blood 111 : 4902-4907, 2008

28） Srikanthan A, et al : Large Retroperitoneal Lymphadenopathy as a Predictor of Venous Thromboembolism in Patients with Disseminated Germ Cell Tumours Treated with Chemo-Therapy. J Clin Oncol 33 : 582-587, 2015

29） Nitta S, et al : Predictors of Venous Thromboembolism Development Before and During Chemotherapy for Advanced Germ Cell Tumor. Jpn J Clin Oncol 50 : 338-343, 2020

30） Tran B, et al : Large Retroperitoneal Lymphadenopathy and Increased Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Metastatic Germ Cell Tumors : A Study by the Global Germ Cell Cancer Group （G3）. Cancer Med 9 : 116-124, 2020

31） International Prognostic Factors Study Group, et al : Prognostic Factors in Patients with Metastatic Germ Cell Tumors Who Experienced Treatment Failure with Cisplatin-Based First-Line Chemotherapy. J Clin Oncol 28 : 4906-4911, 2010

32） Feldman DR, et al : Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. J Cancer 2 : 374-377, 2011

33） Nappi L, et al : Developing a Highly Specific Biomarker for Germ Cell Malignancies : Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol 37 : 3090-3098, 2019